Cancer Survivorship Improvements in cancer screening, early detection, and treatment are
resulting in increased numbers of patients cured of cancer. These persons face a wide …

The evolution of cancer treatment and development of new classes of anticancer therapies
have continued to revolutionize the field of oncology. New therapies including targeted …

Background Several measures including drugs have been tried to reduce anthracycline
cardiotoxicity. The lack of randomized trials prompted this study to assess the role of an …

Aims Left ventricular ejection fraction is used to monitor patients undergoing cardiotoxic
chemotherapy. A decrease in left ventricular ejection fraction represents a relatively late …

Doxorubicin (DOX) is considered as the major culprit in chemotherapy‐induced
cardiotoxicity. Yellow wine polyphenolic compounds (YWPC), which are full of polyphenols …

Introduction Chemotherapy has significantly improved cancer survival rates at the cost of
irreversible and frequent cardiovascular toxicity. As the main dose-dependent adverse …

Objectives Individuals with prior cancer diagnosis are more likely to have low muscle mass
(LMM) than their cancer-free counterparts. Understanding the effects of LMM on the …

The chemotherapeutic effect of doxorubicin (Dox) is limited by cumulative dose-dependent
cardiotoxicity in cancer survivors. Dexrazoxane (DRZ) is approved to prevent Dox-induced …

Background Cardiotoxicity restricts anthracycline and trastuzumab treatment of Human
Epidermal Growth Factor Receptor 2 positive early breast cancer. Endothelial dysfunction …

Opinion statement The past 5 decades have seen significant improvements in outcomes for
pediatric patients with cancer. Unfortunately, children and adolescents who have been …